DECODE enables high-throughput mapping of antibody epitopes at single amino acid resolution

PLoS Biol. 2025 Jan 23;23(1):e3002707. doi: 10.1371/journal.pbio.3002707. eCollection 2025 Jan.

Abstract

Antibodies are extensively used in biomedical research, clinical fields, and disease treatment. However, to enhance the reproducibility and reliability of antibody-based experiments, it is crucial to have a detailed understanding of the antibody's target specificity and epitope. In this study, we developed a high-throughput and precise epitope analysis method, DECODE (Decoding Epitope Composition by Optimized-mRNA-display, Data analysis, and Expression sequencing). This method allowed identifying patterns of epitopes recognized by monoclonal or polyclonal antibodies at single amino acid resolution and predicted cross-reactivity against the entire protein database. By applying the obtained epitope information, it has become possible to develop a new 3D immunostaining method that increases the penetration of antibodies deep into tissues. Furthermore, to demonstrate the applicability of DECODE to more complex blood antibodies, we performed epitope analysis using serum antibodies from mice with experimental autoimmune encephalomyelitis (EAE). As a result, we were able to successfully identify an epitope that matched the sequence of the peptide inducing the disease model without relying on existing antigen information. These results demonstrate that DECODE can provide high-quality epitope information, improve the reproducibility of antibody-dependent experiments, diagnostics and therapeutics, and contribute to discover pathogenic epitopes from antibodies in the blood.

MeSH terms

  • Amino Acids / immunology
  • Animals
  • Antibodies / immunology
  • Antibodies, Monoclonal / immunology
  • Encephalomyelitis, Autoimmune, Experimental* / immunology
  • Epitope Mapping* / methods
  • Epitopes* / immunology
  • Female
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Reproducibility of Results

Substances

  • Epitopes
  • Antibodies
  • Antibodies, Monoclonal
  • Amino Acids

Grants and funding

This work was supported by a JST ERATO grant (H.R.U., no. JPMJER2001), a JST (Moonshot R&D) (K.M., no. JPMJMS2023), Science and Technology Platform Program for Advanced Biological Medicine JP21am0401011, AMED-CREST JP21gm0610006 (AMED/MEXT) (H.R.U.), a Brain/MINDS JP21dm0207049, Grant-in-Aid for Scientific Research (S) JP18H05270 (JSPS KAKENHI) (H.R.U.), a JSPS KAKENHI grant-in-aid for scientific research (c) (K.M., no. 20K06885), a JSPS KAKENHI grant-in-aid for Early-Career Scientists (S.Y. Y., no. 20K16626), a JSPS KAKENHI grant-in-aid for Early-Career Scientists (T. T. M., no. 20K16498), a grant-in-aid from the Human Frontier Science Program (H.R.U.), a MEXT Quantum Leap Flagship Program (MEXT QLEAP) (H.R.U., no. JPMXS0120330644) and an intramural Grant-in-Aid from the RIKEN BDR (H.R.U.).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.